Glazer Capital’s Ibere Pharmaceuticals Units IBER.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-1,000
Closed -$10K – 519
2022
Q4
$10K Hold
1,000
– – ﹤0.01% 471
2022
Q3
$10K Hold
1,000
– – ﹤0.01% 636
2022
Q2
$10K Hold
1,000
– – ﹤0.01% 648
2022
Q1
$10K Buy
+1,000
New +$10K ﹤0.01% 514
2021
Q4
– Sell
-211,064
Closed -$2.11M – 1001
2021
Q3
$2.11M Sell
211,064
-14,296
-6% -$143K 0.04% 394
2021
Q2
$2.26M Sell
225,360
-125,988
-36% -$1.26M 0.04% 420
2021
Q1
$3.46M Buy
+351,348
New +$3.51M 0.05% 389

Glazer Capital's IBER.U Position: Q1 2023 in Review

Glazer Capital sold out of Ibere Pharmaceuticals Units (IBER.U) in Q1 2023, closing a stake of 1,000 shares — an estimated $10K sold.

Glazer Capital first reported a position in IBER.U in Q1 2021 and held it in 7 quarters. The position peaked at $3.46M in Q1 2021. 0 funds tracked by Wall St. Rank hold IBER.U as of Q1 2023.

  • Glazer Capital reported no remaining Ibere Pharmaceuticals Units position as of Q1 2023 after selling out during the quarter.
  • Glazer Capital sold 1,000 Ibere Pharmaceuticals Units shares in Q1 2023, an estimated $10K.
  • Glazer Capital first reported a position in Ibere Pharmaceuticals Units in Q1 2021 and held it in 7 quarters.
  • Glazer Capital's Ibere Pharmaceuticals Units position peaked at $3.46M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units as of Q1 2023.

Based on Glazer Capital's 13F filing for Q1 2023, filed 15 May 2023.